Early Child Development and Exposure to Antiepileptic Drugs
Prenatally and Through Breastfeeding
A Prospective Cohort Study on Children of Women With Epilepsy

Gyri Veiby, MD; Bernt A. Engelsen, MD, PhD; Nils Erik Gilhus, MD, PhD

IMPORTANCE Exposure to antiepileptic drugs during pregnancy is associated with adverse effects on psychomotor development.

OBJECTIVES To determine whether signs of impaired development appear already during the first months of life in children exposed prenatally to antiepileptic drugs, and to explore potential adverse effects of antiepileptic drug exposure through breastfeeding.

DESIGN, SETTING, AND PARTICIPANTS Mothers at 13 to 17 weeks of pregnancy were recruited in the population-based, prospective Norwegian Mother and Child Cohort Study from 1999 to 2009. The mothers reported on their child’s motor and social skills, language, and behavior using items from standardized screening tools at 6 months (n = 78 744), 18 months (n = 61 351), and 36 months (n = 44 147) of age. The mothers also provided detailed information on breastfeeding during the first year.

MAIN OUTCOMES AND MEASURES The risk of adverse development in children according to maternal or paternal epilepsy was estimated as the odds ratio with corresponding 95% confidence interval, adjusted for maternal age, parity, education, smoking, breastfeeding, depression/anxiety, folate supplementation, and congenital malformation in the child.

RESULTS At age 6 months, infants of mothers using antiepileptic drugs (n = 223) had a higher risk of impaired fine motor skills compared with the reference group (11.5% vs 4.8%, respectively; odds ratio = 2.1; 95% CI, 1.3-3.2). Use of multiple antiepileptic drugs compared with the reference group was associated with adverse outcome for both fine motor skills (25.0% vs 4.8%, respectively; odds ratio = 4.3; 95% CI, 2.0-9.1) and social skills (22.5% vs 10.2%, respectively; odds ratio = 2.6; 95% CI, 1.2-5.5). Continuous breastfeeding in children of women using antiepileptic drugs was associated with less impaired development at ages 6 and 18 months compared with those with no breastfeeding or breastfeeding for less than 6 months. At 36 months, prenatal antiepileptic drug exposure was associated with adverse development regardless of breastfeeding status during the first year. Children of women with epilepsy who did not use antiepileptic drugs and children of fathers with epilepsy had normal development at 6 months.

CONCLUSIONS AND RELEVANCE Prenatal exposure to antiepileptic drugs was associated with impaired fine motor skills already at age 6 months, especially when the child was exposed to multiple drugs. There were no harmful effects of breastfeeding. Women with epilepsy should be encouraged to breastfeed their children irrespective of antiepileptic drug treatment.

Published online September 23, 2013.

Author Affiliations: Department of Clinical Medicine, Section for Neurology, University of Bergen, Bergen, Norway (Veiby, Engelsen, Gilhus); Department of Neurology, Haukeland University Hospital, Bergen, Norway (Veiby, Engelsen, Gilhus).

Corresponding Author: Gyri Veiby, MD, Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway (gyri.veiby@hotmail.com).
Antiepileptic drugs potentially influence fetal development throughout the pregnancy. Increasing evidence indicates that prenatal exposure to antiepileptic drugs has effects on cognition, motor function, and behavior. Few studies have presented data on development during the first months in children of mothers with epilepsy. Early identification of children at risk could promote appropriate follow-up and intervention.

Deleterious effects of breastfeeding in children of mothers using antiepileptic drugs are of special interest. Breastfeeding is generally encouraged until at least 6 months of age, based on widely documented beneficial effects. This is controversial concerning women with epilepsy as exposure to antiepileptic drugs through breastfeeding could harm the developing infant, similar to the teratogenic effects associated with in utero exposure.

In the prospective Norwegian Mother and Child Cohort Study (MoBa), mothers have reported on their child’s development at ages 6, 18, and 36 months using validated screening instruments and have provided detailed information on breastfeeding during the first year.

The primary aim of this study was to examine whether prenatal exposure to antiepileptic drugs has an effect on development already during the first 6 months. The secondary aim was to explore adverse effects of antiepileptic drug exposure through breastfeeding. Children of mothers using antiepileptic drugs were compared with a large reference group of children without parental epilepsy. Children of fathers and untreated mothers with epilepsy served as internal control groups, accounting for genetic and socioeconomic effects of parental epilepsy.

Methods

Norwegian Mother and Child Cohort Study
The Norwegian Institute of Public Health established MoBa. Pregnant women in Norway attending routine ultrasonographic scanning were invited to participate, recruited from hospitals and maternity units. Provided the mother’s consent, expecting fathers were also invited to participate. The women received a postal invitation prior to their scheduled ultrasonographic examination (pregnancy weeks 13-17) containing the first questionnaire, focusing on medical history before pregnancy. A questionnaire 6 months after delivery focused on child nutrition, health, and development, while questionnaires at 18 and 36 months further explored the child’s developmental status.

From mid-1999 to December 2008, 108,976 children were registered in MoBa. The participation rate for invited pregnancies was 38.5%. Subsequent response rates for the questionnaires at 6, 18, and 36 months were 84.8%, 73.0%, and 60.2%, respectively.

In a substudy, hospital records for mothers with epilepsy residing in western Norway and participating in MoBa were examined, validating the self-reported epilepsy diagnosis and use of antiepileptic drugs.

This study was approved by the Regional Committee for Medical Research Ethics in western Norway. Written informed consent was obtained from all the participants in MoBa.

Assessment of Parental Epilepsy
All 974 children of mothers or fathers with epilepsy in the MoBa cohort at 6 months formed the epilepsy group. The remaining 77,770 children of parents without epilepsy served as the reference group. Use of antiepileptic drugs during pregnancy was reported by the mother in the first MoBa questionnaire (weeks 13-17) as well as recorded in the compulsory Medical Birth Registry by the attending physician and midwife at delivery. In pregnancies with antiepileptic drug use, 93.7% had drug information from MoBa, whereas the remaining 6.3% had additional drug information from the Medical Birth Registry. For pregnancies with drug information from both registers (73.9%), there was 99.5% accordance with recorded type of monotherapy. Antiepileptic drug monotherapy was subgrouped into carbamazepine, lamotrigine, and valproate sodium. The polytherapy group included pregnancies in which more than 1 antiepileptic drug was reported.

Due to both ongoing data collection and loss to follow-up, the numbers of children of parents with and without epilepsy differ at 6, 18, and 36 months.

Measures of Development

The mothers’ rating of the child’s development and behavior provided the main outcome variables. The screening tools in MoBa are based on standardized and validated scales designed to identify difficulties within each developmental domain and are suited for research. The instruments typically assess whether a child has reached critical developmental milestones. Due to space limitations, some domains are represented with selected items from the original scales, aimed at items that are easily observable by parents. All included items are listed in the eAppendix in the Supplement.

Total scores on the developmental scales were dichotomized by cutoff values into adverse or normal range. For scales without predefined cutoff values, adverse outcome was defined as sum scores rarely observed in the reference group (90th-95th percentile range), corresponding to greater than 2 SDs of the mean. Such scores were regarded as representing clinically relevant impairment. Previous MoBa studies on the applied screening instruments have shown good reliability for developmental scores that are distant (>1.5-2.0 SDs) from the mean.

At age 6 months, items measuring motor skills were obtained from the Ages and Stages Questionnaire. Rating of social skills was based on the Ages and Stages Questionnaire, supplied by items from the Bayley Scales of Infant Development. Assessment of difficult temperament was obtained from the Infant Characteristics Questionnaire.

At age 18 months, motor and communication skills were assessed by items from the Ages and Stages Questionnaire. Autistic traits were examined by a 23-item checklist based on the Modified Checklist for Autism in Toddlers, with a cutoff score at 2 or more of 6 critical items or any 3 items of the total scale.
At age 36 months, language skills were based on criteria by Dale et al.,
assessing the child's typical level of sentence completeness. Attention-deficit/hyperactivity disorder symptoms were measured by a MoBa-specific checklist, including items from the Child Behavior Checklist⁴¹-⁻²⁹ and the attention-deficit/hyperactivity disorder criteria from the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). Aggressiveness was assessed by items from the Child Behavior Checklist. The 40-item Social Communication Questionnaire was applied to investigate autistic traits at 36 months, with a cutoff score at 15 or more positive items.¹⁹⁻³⁰

**Perinatal Outcome and Child Weight**

The Medical Birth Registry provided information on preterm delivery (<37 weeks), low birth weight (<2500 g), and major congenital malformations diagnosed during the neonatal period or pediatric follow-up within the first year. Low child weight at 6 weeks, 3 months, and 6 months was defined as weight below the 10th percentile based on the reference population.

**Statistical Analysis**

In the primary analyses, children of mothers with epilepsy were categorized according to prenatal antiepileptic drug exposure and according to postnatal antiepileptic drug exposure through breast milk. Antiepileptic drug exposure during the breastfeeding period was based on recorded medication during pregnancy, assuring continued treatment after delivery. Children of mothers starting antiepileptic drug treatment after delivery were excluded (n = 4). This ensured that adverse effects of antiepileptic drugs via breast milk were assessed only in children who had also been exposed in utero. Continuous breastfeeding required daily breastfeeding for a minimum of 6 months, whereas discontinued breastfeeding was defined as breastfeeding for less than 6 months or not at all.

The analyses were performed using IBM SPSS Statistics version 20 (IBM Corp.). The risk of adverse outcomes was estimated as odds ratio (OR) with the corresponding 95% confidence interval, using unconditional logistic regression and adjustment for potential confounders. When the OR differed considerably from the relative risk, a generalized linear model estimated the adjusted relative risk. Two-sided *P* ≤ .05 was considered statistically significant. Covariates included maternal age (years), maternal education (≤9, 10-12, 13-16, or ≥17 years), maternal depression/anxiety (Hopkins Symptom Checklist),³¹ breastfeeding duration (months), smoking during pregnancy (yes or no), folate supplementation (preconception and/or during first trimester), child’s birth order (first, second, or third or later), low birth weight, preterm delivery, and major malformation.

To avoid potential sample distortions caused by missing data in the developmental scales, a maximum likelihood estimation procedure was applied to impute missing values.³² Developmental scores with 20% or more missing data were excluded.

Explorative analyses are presented in the eAppendix in the Supplement, including stratified analyses and propensity score matching (eTable 1 and eTable 2 in Supplement).³³

**Results**

**Epilepsy Group**

Data 6 months after delivery included 503 children in 490 pregnancies by 441 women with epilepsy. Baseline characteristics of the epilepsy cohort in MoBa have been published previously.¹³ Exposure to antiepileptic drugs during pregnancy was reported in 223 children (44.3%), with the majority as monotherapy (n = 182). The most common monotherapies were lamotrigine (n = 71), carbamazepine (n = 48), and valproate (n = 27). Exposure to polytherapy with antiepileptic drugs was recorded in 41 children (18.4%).

Another 471 children had a father with epilepsy, of whom 37.6% used antiepileptic drugs within 6 months prior to conception.

**Child Health and Development**

Referrals to a specialist owing to developmental delay were increased for children of mothers using antiepileptic drugs compared with the reference group (3.1% vs 1.5%, respectively; unadjusted OR = 2.2; 95% CI, 1.0-4.6). The same was not observed for children of untreated mothers with epilepsy or children of fathers with epilepsy. Other health problems (infant colic, febrile or nonfebrile convulsions, impaired vision or hearing, heart disorder, or asthma) at 6 months were not increased in any of the epilepsy groups.

Children of mothers using antiepileptic drugs scored more often outside the normal range for fine motor skills at 6 months, with similar risks for monotherapy with lamotrigine, carbamazepine, and valproate (Table 1). Children of mothers using multiple antiepileptic drugs had the highest risk for impaired fine motor skills and also had impaired social skills (Table 1). Difficult temperament was not more common in children of mothers with epilepsy compared with the reference group, including mothers using antiepileptic drugs (3.6% vs 5.2%, respectively; adjusted OR = 0.6; 95% CI, 0.3-1.2) and untreated mothers (5.5% vs 5.2%, respectively; adjusted OR = 1.0; 95% CI, 0.6-1.7).

Children of fathers with epilepsy were similar to the reference group for all the developmental outcomes: gross motor skills (9.9% vs 9.8%, respectively; adjusted OR = 1.0; 95% CI, 0.7-1.4), fine motor skills (5.4% vs 4.8%, respectively; adjusted OR = 1.1; 95% CI, 0.8-1.7), social skills (9.4% vs 10.2%, respectively; adjusted OR = 0.9; 95% CI, 0.7-1.2), and difficult temperament (5.6% vs 5.2%, respectively; adjusted OR = 1.1; 95% CI, 0.7-1.6).

**Breastfeeding Effects on Child Development and Weight**

Breastfeeding rates varied within the epilepsy groups and were lowest for women using lamotrigine monotherapy (Figure 1). Exclusive breastfeeding was less common among women using antiepileptic drugs (eTable 3 in Supplement).

Continuous breastfeeding during the first 6 months was associated with a tendency toward improved outcome for all the developmental domains regardless of maternal antiepileptic drug treatment (Figure 2). For carbamazepine and valproate, the discontinuation rate was too low to sepa-
rately evaluate data concerning nonbreastfeeding. However, development in those who were breastfed compared favorably with other subgroups at 6 months (eTable 4 in Supplement).

At 18 months, children in the drug-exposed group had an increased risk of impaired development compared with the reference group (Table 2). The risks tended to be elevated particularly in children with discontinued breastfeeding. Within the drug-exposed group, this was only statistically significant for autistic traits, where 22.4% with discontinued breastfeeding were affected compared with 8.7% of those with prolonged breastfeeding (unadjusted OR = 3.0; 95% CI, 1.2-7.4). At 36 months, the risk of autistic traits was equally high for both groups (Table 2).

Not breastfeeding was associated with an increased risk of low child weight at 6 weeks and was significant for children of women using antiepileptic drugs (Table 3). At 6 months, the frequency of low child weight was similar for the epilepsy and reference groups regardless of breastfeeding status (Table 3).

**Table 1. Risk of Adverse Developmental Outcome at Age 6 Months in Children of Mothers With Epilepsy Compared With the Reference Group**

<table>
<thead>
<tr>
<th>Child Group</th>
<th>No. (%)</th>
<th>OR (95% CI)</th>
<th>No. (%)</th>
<th>OR (95% CI)</th>
<th>No. (%)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference</td>
<td>77770</td>
<td>3648 (4.8)</td>
<td>1 [Reference]</td>
<td>7507 (9.8)</td>
<td>1 [Reference]</td>
<td>7848 (10.2)</td>
</tr>
<tr>
<td>No antiepileptic drug</td>
<td>276</td>
<td>19 (6.9)</td>
<td>1.4 (0.8-2.2)</td>
<td>33 (12.0)</td>
<td>1.2 (0.8-1.8)</td>
<td>37 (13.4)</td>
</tr>
<tr>
<td>Antiepileptic drugs in total</td>
<td>223</td>
<td>25 (11.5)</td>
<td>2.1 (1.3-3.2)</td>
<td>30 (13.7)</td>
<td>1.3 (0.9-1.9)</td>
<td>28 (12.7)</td>
</tr>
<tr>
<td>Monotherapy</td>
<td>182</td>
<td>15 (8.5)</td>
<td>1.6 (0.9-2.7)</td>
<td>21 (11.7)</td>
<td>1.1 (0.7-1.7)</td>
<td>19 (10.5)</td>
</tr>
<tr>
<td>Lamotrigine monotherapy</td>
<td>71</td>
<td>7 (10.1)</td>
<td>1.8 (0.8-3.9)</td>
<td>11 (15.7)</td>
<td>1.5 (0.8-2.9)</td>
<td>9 (12.7)</td>
</tr>
<tr>
<td>Carbamazepine monotherapy</td>
<td>48</td>
<td>5 (10.9)</td>
<td>2.3 (0.9-6.0)</td>
<td>6 (12.6)</td>
<td>1.3 (0.5-3.0)</td>
<td>6 (12.8)</td>
</tr>
<tr>
<td>Valproate sodium monotherapy</td>
<td>27</td>
<td>3 (11.5)</td>
<td>2.1 (0.6-7.3)</td>
<td>2 (7.4)</td>
<td>0.7 (0.2-2.8)</td>
<td>1 (3.7)</td>
</tr>
<tr>
<td>Polytherapy</td>
<td>41</td>
<td>10 (25.0)</td>
<td>4.3 (2.0-9.1)</td>
<td>9 (23.1)</td>
<td>2.1 (1.0-4.4)</td>
<td>9 (22.5)</td>
</tr>
</tbody>
</table>

Abbreviation: OR, odds ratio.  
* Categorized according to maternal antiepileptic drug use during pregnancy.  
* b The ORs with corresponding 95% CIs were adjusted for maternal age, parity, education, folate supplementation, smoking, depression/anxiety, breastfeeding (number of months), and child malformation.  
* P ≤ .05.

**Figure 1. Exclusive or Mixed Breastfeeding at Ages 0 to 6 Months**

Frequency of breastfeeding in epilepsy groups and the reference group at 0 to 6 months after delivery. AED indicates antiepileptic drug.

Discussion

**Key Findings**

Infants of mothers using antiepileptic drugs had an increased risk of delayed fine motor skills at 6 months, with similar risk estimates for monotherapy with lamotrigine, valproate, and carbamazepine. Children exposed to polytherapy had higher risks, with significant effects on both fine motor and social skills. Other developmental measures in the exposed group were within the normal range at this early age. Children of mothers with epilepsy who did not use antiepileptic drugs and children of fathers with epilepsy had normal development at 6 months, indicating that adverse effects in the drug-exposed group were not a result of genetic factors.

Breastfeeding was not associated with adverse development at ages 6 to 36 months in children of mothers using antiepileptic drugs. On the contrary, there was a trend toward a more favorable outcome in children who were continuously breastfed, especially for early autistic traits. Breastfeeding in the drug-exposed group was also associated with a lower risk of poor weight gain during the postnatal period.
Continuous breastfeeding during the first year was less common among women using antiepileptic drugs, especially regarding lamotrigine monotherapy, compared with both those not using drugs and the reference population. This may indicate that antiepileptic drugs are regarded by patients, midwives, and physicians as a relative contraindication for breastfeeding.

Figure 2. Risk of Adverse Development Score at 6 Months in Children of Mothers With Epilepsy According to Breastfeeding

Table 2. Risk of Adverse Development at Ages 18 and 36 Months in Children of Antiepileptic Drug–Treated Mothers Categorized According to Breastfeeding

<table>
<thead>
<tr>
<th>Adverse Outcome</th>
<th>Reference, %</th>
<th>Breastfeeding ≥6 mo</th>
<th>Breastfeeding &lt;6 mo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%)</td>
<td>OR (95% CI)</td>
<td>No. (%)</td>
</tr>
<tr>
<td>Child aged 18 mo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fine motor skills</td>
<td>12.4</td>
<td>22 (19.6)</td>
<td>1.7 (1.1-2.8)*</td>
</tr>
<tr>
<td>Gross motor skills</td>
<td>8.6</td>
<td>13 (11.5)</td>
<td>1.2 (0.7-2.3)</td>
</tr>
<tr>
<td>Autistic traits</td>
<td>7.8</td>
<td>9 (8.7)</td>
<td>1.0 (0.5-2.0)</td>
</tr>
<tr>
<td>Communication skills</td>
<td>10.6</td>
<td>20 (18.0)</td>
<td>1.7 (1.1-2.9)*</td>
</tr>
<tr>
<td>Child aged 36 mo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autistic traits</td>
<td>1.5</td>
<td>4 (5.0)</td>
<td>3.1 (1.1-8.7)*</td>
</tr>
<tr>
<td>Sentence skills</td>
<td>4.8</td>
<td>9 (11.1)</td>
<td>2.3 (1.3-4.7)*</td>
</tr>
<tr>
<td>ADHD symptoms</td>
<td>4.0</td>
<td>7 (8.5)</td>
<td>2.2 (1.0-5.2)</td>
</tr>
<tr>
<td>Aggressive symptoms</td>
<td>4.1</td>
<td>4 (4.9)</td>
<td>1.3 (0.5-3.7)</td>
</tr>
</tbody>
</table>

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; AED, antiepileptic drug; OR, odds ratio.
* More than 2 SDs from the mean.
† Absent or discontinued breastfeeding (median duration of breastfeeding, 1 month).
‡ The ORs with corresponding 95% CIs were adjusted for maternal age, parity, education, smoking, folate supplementation, depression/anxiety at assessment, and child malformation.
§ A total of 184 children of mothers with epilepsy using AEDs were compared with a reference group of 60 583 children.
¶ P ≤.05.
‖ A total of 139 children of mothers with epilepsy using AEDs were compared with a reference group of 43 571 children.
Interpretation

Recent studies have provided new insights into the long-term effects of prenatal exposure to antiepileptic drugs, with the majority reporting some degree of adverse development.3,6,7,34,35 According to our findings, assessment of fine motor skills may be especially suited for early identification of children at risk and could initiate the follow-up of these children. There are limited previous reports on development during infancy in children exposed in utero to antiepileptic drugs, and no reports systematically explore effects of breastfeeding during this early period. Evidence to determine whether maternal use of antiepileptic drugs has symptomatic effects on the infant has not been established earlier.36 We could not identify any deleterious effects of breastfeeding on early development in children of mothers using antiepileptic drugs. Similarly, Meador et al37 found no harmful effects of breastfeeding on child IQ at age 3 years. The beneficial role of breastfeeding is widely documented, including effects on cognition.38 In maternal epilepsy, professional recommendations must balance such benefits against potential harmful effects of continued drug exposure through breast milk. This has been of concern especially for lamotrigine and other newer-generation antiepileptic drugs, which penetrate into breast milk in relatively small amounts.36,38,39 Antiepileptic drugs cross the placenta in clinically relevant amounts,36,39 with a dose-dependent teratogenicity.40 However, ingested concentrations from breast milk are substantially lower than in utero exposure.39 Whereas fetal exposure to antiepileptic drugs is similar to maternal plasma concentrations, infant and maternal plasma concentrations are highly variable and depend on a variety of factors.41 Phenytoin, phenobarbital, carbamazepine, and valproate probably do not transfer to breast milk in significant amounts.36 Antiepileptic drugs with low protein binding, such as levetiracetam and gabapentin, accumulate in breast milk but are probably efficiently eliminated by the infant.39 For lamotrigine and oxcarbazepine, reduced hepatic elimination in the newborn combined with moderate transfer via breast milk can result in clinically relevant plasma concentrations in the infant.39,41,42 Case reports describing withdrawal seizures as a result of discontinued breastfeeding33 and serious apnea in a newborn exposed to lamotrigine via breast milk44 underline the importance of cautious observation during the perinatal period. Previous Norwegian guidelines regarding lamotrigine probably explain the low rate of breastfeeding among MoBa mothers using lamotrigine. However, most reports on lamotrigine exposure via breast milk have not observed any adverse effects.38,41 Our study supports that positive effects of breastfeeding outweigh any negative effects, including for mothers treated with lamotrigine or polytherapy.

In the drug-exposed group, the risk of autistic traits at age 18 months was substantially higher for children who discontinued breastfeeding compared with those with prolonged breastfeeding. Previous reports have described a link between autism spectrum disorders and suboptimal breastfeeding.45,46 Potential mechanisms include nutritional and immunological factors, maternal comorbidity, socioeconomic status, and psychological effects of breastfeeding. Autistic traits at this early age can be associated with general cognitive delay and behavioral problems and not necessarily with true autism.47 At 36 months, children of drug-treated mothers with epilepsy had more autistic traits regardless of previous breastfeeding, indicating general and specific risks of autism at this age.

Study Strengths and Limitations

This study included children of mothers both with and without antiepileptic drug treatment and of fathers with epilepsy
recruited in an unselected manner and followed up prospectively in a large national cohort. The participation rate of 38.5% at first assessment is in accordance with the rate from similar registers.48 Systematic bias due to nonparticipants is a potential concern. However, exposure and outcome associations were not biased in a previous MoBa study,19 and the prevalence of epilepsy did not differ from the total population.49,50 Mothers’ ratings of the child were based on validated screening tools. Such ratings provide adequate information on the child’s development46,27,51 but do not correspond directly with medical diagnosis. Adjusting for maternal anxiety/depression should partly control for effects of maternal mood on rating of the child. Stratified analysis and propensity score matching showed that the results were not due to differences in baseline variables. Still, residual confounding due to unmeasured parameters such as severity and type of mothers’ epilepsy may theoretically contribute to some of the observed drug-exposure associations. Breastfeeding status is strongly related to socioeconomic factors,52 but such confounding has been accounted for in our study. Reported drug use during pregnancy was applied as a proxy for antiepileptic drug treatment after delivery. This could potentially lead to misclassification of drug exposure via breast milk, although most likely only for a minor percentage as discontinuation of antiepileptic drugs during the postnatal period is not recommended. No mothers in the validation study discontinued antiepileptic drugs during pregnancy or within the first year post partum. Thus, children in the drug-treated group were most likely exposed during the entire pregnancy. Limitations of this study were that specific trimester effects, antiepileptic drug dosages, and concentrations in breast milk could not be investigated.

Conclusions

Prenatal exposure to antiepileptic drugs was associated with a higher risk of impaired fine motor skills at age 6 months, especially in children exposed to multiple antiepileptic drugs. Awareness of such signs may promote early identification of children at risk. Breastfeeding in women using antiepileptic drugs was not associated with any harmful effects on child development at 6 to 36 months of age, and it protected against low weight during the postnatal period. Women with epilepsy should be encouraged to breastfeed their children irrespective of antiepileptic medication use.

ARTICLE INFORMATION

Accepted for Publication: July 10, 2013.

Author Contributions: Dr Veiby had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: All authors.
Acquisition of data: All authors.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: Veiby.
Critical revision of the manuscript for important intellectual content: Engelsen, Gilhus.
Statistical analysis: Veiby.
Study supervision: Engelsen, Gilhus.

Conflict of Interest Disclosures: Dr Veiby has received travel support from UCB Pharma and lecture fees from GlaxoSmithKline. Dr Engelsen has received travel support from GlaxoSmithKline and lecture fees from Lundbeck. No other disclosures were reported.

Funding/Support: This work was supported by the Norwegian Association for Epilepsy. The Norwegian Mother and Child Cohort Study is supported by the Norwegian Ministry of Health and the Ministry of Education and Research, grant NO1-E5-75558 from the National Institute of Environmental Health Sciences, grants U01 NS047537-01 and U01 NS047537-06A1 from the National Institute of Neurological Disorders and Stroke, and grant 151918/S10 from the Norwegian Research Council/FUGE.

Role of the Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

Additional Contributions: We are grateful to all the participating families in Norway who take part in this ongoing cohort study. Solveig Glad, MD, PhD, proofread the manuscript.

REFERENCES

19. Snow AV, Lecavalier L. Sensitivity and specificity of the Modified Checklist for Autism in...


